hmr 1766 has been researched along with Hypoxia in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dahal, BK; Dumitrascu, R; Eickels, Mv; Fuchs, B; Ghofrani, HA; Grimminger, F; Hackemack, S; Medebach, T; Mittal, M; Pullamsetti, SS; Savai, R; Schermuly, RT; Seeger, W; Weissmann, N | 1 |
1 other study(ies) available for hmr 1766 and Hypoxia
Article | Year |
---|---|
The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice.
Topics: Animals; Cardiomegaly; Cyclic GMP; Guanylate Cyclase; Hemodynamics; Hypertension, Pulmonary; Hypoxia; Mice; Myocytes, Smooth Muscle; ortho-Aminobenzoates; Pulmonary Artery; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Superoxides; Vasoconstriction | 2009 |